{
    "root": "316b0bb6-c15c-c1d0-e063-6394a90aabb4",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "XARELTO",
    "value": "20250328",
    "ingredients": [
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "POLYETHYLENE GLYCOL 3350",
            "code": "G2M7P15E5P",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "RIVAROXABAN",
            "code": "9NDF7JZ4M3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_68579"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "ANHYDROUS CITRIC ACID",
            "code": "XF417D3PSL",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30769"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_29864"
        },
        {
            "name": "CARBOXYMETHYLCELLULOSE SODIUM, UNSPECIFIED",
            "code": "K679OBS311",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_85146"
        },
        {
            "name": "SODIUM BENZOATE",
            "code": "OJ245FE5EU",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_113455"
        },
        {
            "name": "SUCRALOSE",
            "code": "96K6UQ3ZD4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32159"
        },
        {
            "name": "XANTHAN GUM",
            "code": "TTV12P4NEE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_189560"
        }
    ],
    "indications": {
        "text": "xarelto factor xa inhibitor indicated : reduce risk stroke systemic embolism nonvalvular atrial fibrillation ( 1.1 ) treatment deep vein thrombosis ( dvt ) ( 1.2 ) treatment pulmonary embolism ( pe ) ( 1.3 ) reduction risk recurrence dvt pe ( 1.4 ) prophylaxis dvt , may lead pe patients undergoing knee hip replacement surgery ( 1.5 ) prophylaxis venous thromboembolism ( vte ) acutely ill medical patients ( 1.6 ) reduce risk major cardiovascular events patients coronary artery disease ( cad ) ( 1.7 ) reduce risk major thrombotic vascular events patients peripheral artery disease ( pad ) , including patients recent lower extremity revascularization due symptomatic pad ( 1.8 ) treatment vte reduction risk recurrent vte pediatric patients birth less 18 years ( 1.9 ) thromboprophylaxis pediatric patients 2 years older congenital heart disease fontan procedure ( 1.10 )",
        "doid_entities": [
            {
                "text": "stroke (DOID:6713)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6713"
            },
            {
                "text": "atrial fibrillation (DOID:0060224)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0060224"
            },
            {
                "text": "thrombosis (DOID:0060903)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0060903"
            },
            {
                "text": "pulmonary embolism (DOID:9477)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9477"
            },
            {
                "text": "coronary artery disease (DOID:3393)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3393"
            },
            {
                "text": "artery disease (DOID:0050828)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0050828"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "peripheral artery disease (DOID:0050830)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0050830"
            },
            {
                "text": "congenital heart disease (DOID:1682)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1682"
            },
            {
                "text": "heart disease (DOID:114)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_114"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "nonvalvular atrial fibrillation : 15 20 mg , daily food ( 2.1 ) treatment dvt and/or pe : 15 mg orally twice daily food first 21 days followed 20 mg orally daily food remaining treatment ( 2.1 ) reduction risk recurrence dvt and/or pe patients continued risk dvt and/or pe : 10 mg daily without food , least 6 months standard anticoagulant treatment ( 2.1 ) prophylaxis dvt following hip knee replacement surgery : 10 mg orally daily without food ( 2.1 ) prophylaxis vte acutely ill medical patients risk thromboembolic complications high risk bleeding : 10 mg daily , without food , hospital hospital discharge total recommended duration 31 39 days ( 2.1 ) cad pad : 2.5 mg orally twice daily without food , combination aspirin ( 75\u2013100 mg ) daily ( 2.1 ) pediatric patients : dosing recommendations full prescribing information ( 2.2 )",
        "doid_entities": [
            {
                "text": "atrial fibrillation (DOID:0060224)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0060224"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "xarelto \u00ae ( rivaroxaban ) tablets available strengths packages listed : 2.5 mg tablets round , light yellow , film-coated triangle pointing `` 2.5 `` marked one side `` xa `` side . tablets supplied packages listed : ndc 50458-577-60 bottle containing 60 tablets ndc 50458-577-18 bottle containing 180 tablets ndc 50458-577-10 blister package containing 100 tablets ( 10 blister cards containing 10 tablets ) 10 mg tablets round , light red , biconvex film-coated tablets marked triangle pointing `` 10 `` one side , `` xa `` side . tablets supplied packages listed : ndc 50458-580-30 bottle containing 30 tablets ndc 50458-580-90 bottle containing 90 tablets ndc 50458-580-10 blister package containing 100 tablets ( 10 blister cards containing 10 tablets ) 15 mg tablets round , red , biconvex film-coated tablets triangle pointing `` 15 `` marked one side `` xa `` side . tablets supplied packages listed : ndc 50458-578-30 bottle containing 30 tablets ndc 50458-578-90 bottle containing 90 tablets ndc 50458-578-10 blister package containing 100 tablets ( 10 blister cards containing 10 tablets ) 20 mg tablets triangle-shaped , dark red film-coated tablets triangle pointing `` 20 `` marked one side `` xa `` side . tablets supplied packages listed : ndc 50458-579-30 bottle containing 30 tablets ndc 50458-579-90 bottle containing 90 tablets ndc 50458-579-89 bulk bottle containing 1000 tablets ndc 50458-579-10 blister package containing 100 tablets ( 10 blister cards containing 10 tablets ) starter pack treatment deep vein thrombosis treatment pulmonary embolism : ndc 50458-584-51 30-day starter blister pack containing 51 tablets : 42 tablets 15 mg 9 tablets 20 mg xarelto \u00ae ( rivaroxaban ) oral suspension available strength package listed : ndc 50458-575-01 supplied white off-white granules amber glass bottle containing 155 mg rivaroxaban packaged two oral dosing syringes . reconstitution 150 ml purified water , 1 ml suspension contains 1 mg rivaroxaban .",
    "adverseReactions": "xarelto contraindicated patients : active pathological bleeding [ ( 5.2 ) ] severe hypersensitivity reaction xarelto ( e.g . , anaphylactic ) [ ( 6.2 ) ]",
    "indications_original": "XARELTO is a factor Xa inhibitor indicated: to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation ( 1.1 ) for treatment of deep vein thrombosis (DVT) ( 1.2 ) for treatment of pulmonary embolism (PE) ( 1.3 ) for reduction in the risk of recurrence of DVT or PE ( 1.4 ) for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery ( 1.5 ) for prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients ( 1.6 ) to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) ( 1.7 ) to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD ( 1.8 ) for treatment of VTE and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years ( 1.9 ) for thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure ( 1.10 )",
    "contraindications_original": "Nonvalvular Atrial Fibrillation : 15 or 20 mg, once daily with food ( 2.1 ) Treatment of DVT and/or PE : 15 mg orally twice daily with food for the first 21 days followed by 20 mg orally once daily with food for the remaining treatment ( 2.1 ) Reduction in the Risk of Recurrence of DVT and/or PE in patients at continued risk for DVT and/or PE : 10 mg once daily with or without food, after at least 6 months of standard anticoagulant treatment ( 2.1 ) Prophylaxis of DVT Following Hip or Knee Replacement Surgery : 10 mg orally once daily with or without food ( 2.1 ) Prophylaxis of VTE in Acutely Ill Medical Patients at Risk for Thromboembolic Complications Not at High Risk of Bleeding : 10 mg once daily, with or without food, in hospital and after hospital discharge for a total recommended duration of 31 to 39 days ( 2.1 ) CAD or PAD : 2.5 mg orally twice daily with or without food, in combination with aspirin (75\u2013100 mg) once daily ( 2.1 ) Pediatric Patients: See dosing recommendations in the Full Prescribing Information ( 2.2 )",
    "warningsAndPrecautions_original": "XARELTO\n       \n \n  \u00ae (rivaroxaban) Tablets are available in the strengths and packages listed below:\n      \n\n \n                  \n                     2.5 mg tablets are round, light yellow, and film-coated with a triangle pointing down above a \"2.5\" marked on one side and \"Xa\" on the other side. The tablets are supplied in the packages listed: \t\t\t\t\t\t\t\n        \n  \n   \n                           \n                           \n                           \n                              \n                                 NDC 50458-577-60\n                                 Bottle containing 60 tablets\n                              \n                              \n                                 NDC 50458-577-18\n                                 Bottle containing 180 tablets\n                              \n                              \n                                 NDC 50458-577-10\n                                 Blister package containing 100 tablets (10 blister cards containing 10 tablets each)\n                              \n                           \n                        \n                     \n                     10 mg tablets are round, light red, biconvex film-coated tablets marked with a triangle pointing down above a \"10\" on one side, and \"Xa\" on the other side. The tablets are supplied in the packages listed: \t\t\t\t\t\t\t\n        \n  \n   \n                           \n                           \n                           \n                              \n                                 NDC 50458-580-30\n                                 Bottle containing 30 tablets\n                              \n                              \n                                 NDC 50458-580-90\n                                 Bottle containing 90 tablets\n                              \n                              \n                                 NDC 50458-580-10\n                                 Blister package containing 100 tablets (10 blister cards containing 10 tablets each)\n                              \n                           \n                        \n                     \n                     15 mg tablets are round, red, biconvex film-coated tablets with a triangle pointing down above a \"15\" marked on one side and \"Xa\" on the other side. The tablets are supplied in the packages listed: \t\t\t\t\t\t\t\n        \n  \n   \n                           \n                           \n                           \n                              \n                                 NDC 50458-578-30\n                                 Bottle containing 30 tablets\n                              \n                              \n                                 NDC 50458-578-90\n                                 Bottle containing 90 tablets\n                              \n                              \n                                 NDC 50458-578-10\n                                 Blister package containing 100 tablets (10 blister cards containing 10 tablets each)\n                              \n                           \n                        \n                     \n                     20 mg tablets are triangle-shaped, dark red film-coated tablets with a triangle pointing down above a \"20\" marked on one side and \"Xa\" on the other side. The tablets are supplied in the packages listed: \t\t\t\t\t\t\t\n        \n  \n   \n                           \n                           \n                           \n                              \n                                 NDC 50458-579-30\n                                 Bottle containing 30 tablets\n                              \n                              \n                                 NDC 50458-579-90\n                                 Bottle containing 90 tablets\n                              \n                              \n                                 NDC 50458-579-89\n                                 Bulk bottle containing 1000 tablets\n                              \n                              \n                                 NDC 50458-579-10\n                                 Blister package containing 100 tablets (10 blister cards containing 10 tablets each)\n                              \n                           \n                        \n                     \n                     Starter Pack for treatment of deep vein thrombosis and treatment of pulmonary embolism: \t\t\t\t\t\t\t\n        \n  \n   \n                           \n                           \n                           \n                              \n                                 NDC 50458-584-51\n                                 30-day starter blister pack containing 51 tablets: 42 tablets of 15 mg and 9 tablets of 20 mg\n                              \n                           \n                        \n                     \n                  \n                  XARELTO\n       \n \n  \u00ae (rivaroxaban) for oral suspension is available in the strength and package listed below:\n      \n\n \n                  \n                     \n                     \n                     \n                        \n                           NDC 50458-575-01\n                           Supplied as white to off-white granules in an amber glass bottle containing 155 mg rivaroxaban packaged with two oral dosing syringes. After reconstitution with 150 mL of purified water, 1 mL of the suspension contains 1 mg rivaroxaban.",
    "adverseReactions_original": "XARELTO is contraindicated in patients with:\n                  \n                     active pathological bleeding \n        \n  \n   [see \n         \n   \n    Warnings and Precautions (5.2)]\n        \n  \n   \n                     \n                     severe hypersensitivity reaction to XARELTO (e.g., anaphylactic reactions) \n        \n  \n   [see \n         \n   \n    Adverse Reactions (6.2)]",
    "drug": [
        {
            "name": "XARELTO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        }
    ]
}